Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2019 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics to Present Data on Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting 2019

NEWARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients...
November 06, 2018 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Announces Presentations on Tarloxotinib at the 30th EORTC-NCI-AACR Symposium

FREMONT, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
October 01, 2018 08:00 ET | Source: Rain Therapeutics

Lori Kunkel, M.D. Joins the Rain Therapeutics Scientific Advisory Board (SAB)

FREMONT, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
August 22, 2018 16:01 ET | Source: Rain Therapeutics

Rain Therapeutics Announces Collaborator Presentations on Tarloxotinib at Two Upcoming Conferences

FREMONT, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
June 05, 2018 08:01 ET | Source: Rain Therapeutics

Rain Therapeutics Announces Collaborator Presentations on Tarloxotinib at the 5th International Conference on Tumor Microenvironment and Cellular Stress

FREMONT, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
May 21, 2018 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Closes $18 Million Series A Financing

FREMONT, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients...